| 2026-08-11 | Press release | Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Co |
| 2026-08-06 | Press release | Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update |
| 2026-07-22 | Press release | Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Vir |
| 2026-07-21 | Press release | Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors |
| 2026-07-15 | Press release | Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision |
| 2026-06-26 | Press release | Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Seri |
| 2026-06-25 | Press release | Phio Pharmaceuticals Announces “How siRNA Therapy can Change the Course of Cancer Treatment” in a Fireside C |
| 2026-06-24 | Press release | Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762 |
| 2026-06-18 | Press release | Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026 |
| 2026-05-26 | Press release | Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Seri |
| 2026-05-12 | Press release | Phio Pharmaceuticals Announces “Innovations in Skin Cancer Treatment and Prevention” in a Fireside Chat with |
| 2026-05-07 | Press release | Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update |
| 2026-04-23 | Press release | Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Seri |
| 2026-04-13 | Press release | Phio Pharmaceuticals Announces “Nobel Prize Winning Science Takes on Skin Cancer” in a Fireside Chat with Fo |
| 2026-04-09 | Press release | Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026 |
| 2026-03-30 | Press release | Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762 |
| 2026-03-23 | Press release | Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from S |
| 2026-03-16 | Press release | Phio Pharmaceuticals Announces “A Groundbreaking Approach to Treating Skin Cancer” in a Fireside Chat with F |
| 2026-03-10 | Press release | Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT |
| 2026-03-05 | Press release | Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Seri |
| 2026-03-05 | Press release | Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update |
| 2026-02-19 | Press release | Phio Pharmaceuticals Aligns Leadership Team to Support Next Stage Development of PH-762 and Advancement of PH-894 |
| 2026-02-10 | Press release | Phio Announces Safety Monitoring Committee's (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Tri |
| 2026-01-26 | Press release | Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference |
| 2026-01-20 | Press release | Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous |
| 2025-12-23 | Press release | Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762 |
| 2025-11-25 | Press release | Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762 |
| 2025-11-17 | Press release | Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress |
| 2025-11-13 | Press release | Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update |
| 2025-11-07 | Press release | Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough |
| 2025-11-07 | Press release | Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762 |
| 2025-11-03 | Press release | Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Tria |
| 2025-11-03 | Press release | Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds |
| 2025-10-31 | Press release | Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director |
| 2025-10-21 | Press release | Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Seri |
| 2025-09-23 | Press release | Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Seri |
| 2025-09-18 | Press release | Phio Pharmaceuticals to Present at the Life Sciences Future Conference |
| 2025-09-03 | Press release | Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference |
| 2025-07-25 | Press release | Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance |
| 2025-07-25 | Press release | Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort |